Elan unlikely target for Biogen given latter's focus on MS drug BG-12 Financial Times In addition, the company is advancing daclizumab, an IL-2R antibody, in what will be the largest MS study ever conducted. Data is expected in 2014. On 13 August 2012, Irish pharmaceutical company Elan announced it would spin off its drug discovery arm ... |
